The Changing Landscape of Treatment for Cystic Fibrosis Related Diabetes

The Changing Landscape of Treatment for Cystic Fibrosis Related Diabetes

Objective: Patients with Cystic Fibrosis related diabetes [CFRD] are treated with insulin and high calorie diets to maintain body mass. The combined CFTR modulator elexacaftor/tezacaftor/ivacaftor [ETI] decreases pulmonary exacerbations and improves nutritional status. We reviewed the effects of ETI...

Full description

Bibliographic Details
Main Authors:	Mehdia Amini, Kevin Yu, Jessica Liebich, Vaishaliben Ahir, Emily Wood, Stewart Albert, Sandeep Dhindsa
Format:	Article
Language:	English
Published:	Elsevier 2024-03-01
Series:	Journal of Clinical & Translational Endocrinology
Subjects:	Cystic fibrosis Diabetes Elexacaftor Tezacaftor Ivacaftor
Online Access:	http://www.sciencedirect.com/science/article/pii/S2214623724000036

Similar Items

Cystic fibrosis modulator therapy can reverse cystic bronchiectasis
by: Peter G. Middleton, et al.
Published: (2023-07-01)

Real‐life efficacy and safety of elexacaftor/tezacaftor/ivacaftor on severe cystic fibrosis lung disease patients
by: Renate Kos, et al.
Published: (2022-12-01)

Longitudinal profiling of the intestinal microbiome in children with cystic fibrosis treated with elexacaftor-tezacaftor-ivacaftor
by: Seth A. Reasoner, et al.
Published: (2024-02-01)

Editorial: Real-world experience with CFTR modulator therapy
by: Burkhard Tümmler, et al.
Published: (2023-11-01)

Post-approval studies with the CFTR modulators Elexacaftor-Tezacaftor—Ivacaftor
by: Burkhard Tümmler, et al.
Published: (2023-03-01)

Elexacaftor-Tezacaftor-Ivacaftor as a Final Frontier in the Treatment of Cystic Fibrosis: Definition of the Clinical and Microbiological Implications in a Case-Control Study
by: Giuseppe Migliorisi, et al.
Published: (2022-05-01)

Elexacaftor/Tezacaftor/Ivacaftor in Patients with Cystic Fibrosis Homozygous for the <i>F508del</i> Mutation and Advanced Lung Disease: A 48-Week Observational Study
by: Vincenzo Carnovale, et al.
Published: (2022-02-01)

Effects of elexacaftor/tezacaftor/ivacaftor therapy on mental health of patients with cystic fibrosis
by: Linus Piehler, et al.
Published: (2023-04-01)

Precision Medicine Based on CFTR Genotype for People with Cystic Fibrosis
by: Haq I, et al.
Published: (2022-02-01)

Real-world effectiveness of elexacaftor/tezacaftor/ivacaftor on the burden of illness in adolescents and adults with cystic fibrosis
by: Thomas Keens, et al.
Published: (2024-04-01)

Successful pregnancy in a cystic fibrosis patient with a severe impairment of lung function receiving Elexacaftor-Tezacaftor-Ivacaftor
by: Zisis Balmpouzis, et al.
Published: (2022-01-01)

Effects of Elexacaftor/Tezacaftor/Ivacaftor on Cardiorespiratory Polygraphy Parameters and Respiratory Muscle Strength in Cystic Fibrosis Patients with Severe Lung Disease
by: Alessandro Giallongo, et al.
Published: (2023-02-01)

CFTR Modulators in People with Cystic Fibrosis: Real-World Evidence in France
by: Lucile Regard, et al.
Published: (2022-05-01)

Resolution of long standing hypergammaglobulinemic purpura of Waldenström after initiating treatment for cystic fibrosis with Elexacaftor–Tezacaftor–Ivacaftor
by: Kimberly Tantuco, MD, et al.
Published: (2024-02-01)

One year of treatment with elexacaftor/tezacaftor/ivacaftor in patients with cystic fibrosis homozygous for the F508del mutation causes a significant increase in liver biochemical indexes
by: Alice Castaldo, et al.
Published: (2024-01-01)

Elexacaftor-Tezacaftor-Ivacaftor in 2 cystic fibrosis adults homozygous for M1101K with end-stage lung disease
by: Winnie M. Leung, et al.
Published: (2023-01-01)

Malassezia Folliculitis following Triple Therapy for Cystic Fibrosis
by: Federica Li Pomi, et al.
Published: (2022-09-01)

Effectiveness of Elexacaftor/Tezacaftor/Ivacaftor Therapy in Three Subjects with the Cystic Fibrosis Genotype Phe508del/Unknown and Advanced Lung Disease
by: Vito Terlizzi, et al.
Published: (2021-07-01)

Spirometric and anthropometric improvements in response to elexacaftor/tezacaftor/ivacaftor depending on age and lung disease severity
by: Katharina Schütz, et al.
Published: (2023-07-01)

Longitudinal microbial and molecular dynamics in the cystic fibrosis lung after Elexacaftor–Tezacaftor–Ivacaftor therapy
by: Christian Martin, et al.
Published: (2023-12-01)

Efficacy and safety profile of elexacaftor-tezacaftor-ivacaftor triple therapy on cystic fibrosis: a systematic review and single arm meta-analysis
by: Wenye Xu, et al.
Published: (2023-12-01)

Pediatric population with cystic fibrosis in the centre of Portugal: candidates for new therapies
by: Juliana Roda, et al.
Published: (2022-03-01)

Use of elexacaftor/tezacaftor/ivacaftor leads to changes in detection frequencies of Staphylococcus aureus and Pseudomonas aeruginosa dependent on age and lung function in people with cystic fibrosis
by: Anna-Maria Dittrich, et al.
Published: (2024-02-01)

Efficacy and Safety of Elexacaftor-Tezacaftor-Ivacaftor in the Treatment of Cystic Fibrosis: A Systematic Review
by: Nikoletta Kapouni, et al.
Published: (2023-03-01)

Impact of CFTR Modulators on Beta-Cell Function in Children and Young Adults with Cystic Fibrosis
by: Claudia Piona, et al.
Published: (2022-07-01)

Qualitative and quantitative evaluation of computed tomography changes in adults with cystic fibrosis treated with elexacaftor-tezacaftor-ivacaftor: a retrospective observational study
by: Sabine Dettmer, et al.
Published: (2023-09-01)

Multimodal analysis of granulocytes, monocytes, and platelets in patients with cystic fibrosis before and after Elexacaftor–Tezacaftor–Ivacaftor treatment
by: Hanna Schmidt, et al.
Published: (2023-06-01)

Response to Elexacaftor/Tezacaftor/Ivacaftor in people with cystic fibrosis with the N1303K mutation: Case report and review of the literature
by: Maria G. Tupayachi Ortiz, et al.
Published: (2024-03-01)

Real-World Safety of CFTR Modulators in the Treatment of Cystic Fibrosis: A Systematic Review
by: Renée V. E. Dagenais, et al.
Published: (2020-12-01)

Real-life impact of highly effective CFTR modulator therapy in children with cystic fibrosis
by: Margarete Olivier, et al.
Published: (2023-05-01)

Long-Term Follow-Up of Health-Related Quality of Life and Short-Term Intervention with CFTR Modulator Therapy in Adults with Cystic Fibrosis: Evaluation of Changes over Several Years with or without 33 Weeks of CFTR Modulator Therapy
by: Wolfgang Gruber, et al.
Published: (2023-10-01)

Longitudinal changes in habitual physical activity in adult people with cystic fibrosis in the presence or absence of treatment with elexacaftor/tezacaftor/ivacaftor
by: Wolfgang Gruber, et al.
Published: (2024-02-01)

Gene therapy-emulating small molecule treatments in cystic fibrosis airway epithelial cells and patients
by: Q. Yang, et al.
Published: (2019-12-01)

Elexacaftor-tezacaftor-ivacaftor in patients with cystic fibrosis ineligible for clinical trials: a 24-week observational study
by: Libor Fila, et al.
Published: (2023-06-01)

Impact of elexacaftor/tezacaftor/ivacaftor on lung function, nutritional status, pulmonary exacerbation frequency and sweat chloride in people with cystic fibrosis: real-world evidence from the German CF RegistryResearch in context
by: Sivagurunathan Sutharsan, et al.
Published: (2023-09-01)

Optimizing CFTR modulator therapy management for cystic fibrosis through the ReX platform
by: Karin Yaacoby-Bianu, et al.
Published: (2023-12-01)

Fetal drug exposure after maternally administered CFTR modulators Elexacaftor/Tezacaftor/Ivacaftor in a rat model
by: Danni Li, et al.
Published: (2024-02-01)

CFTR Function Restoration upon Elexacaftor/Tezacaftor/Ivacaftor Treatment in Patient-Derived Intestinal Organoids with Rare <i>CFTR</i> Genotypes
by: Juliet W. Lefferts, et al.
Published: (2023-09-01)

Clinical efficacy of elexacaftor-tezacaftor-ivacaftor in an adolescent with homozygous G85E cystic fibrosis
by: Elena Stekolchik, et al.
Published: (2022-01-01)

Simultaneous Quantification of Ivacaftor, Tezacaftor, and Elexacaftor in Cystic Fibrosis Patients’ Plasma by a Novel LC–MS/MS Method
by: Federica Pigliasco, et al.
Published: (2023-02-01)